Linked Life Data

16103092

Source:http://linkedlifedata.com/resource/pubmed/id/16103092

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16103092rdf:typepubmed:Citationlld:pubmed
pubmed-article:16103092lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:16103092lifeskim:mentionsumls-concept:C2239176lld:lifeskim
pubmed-article:16103092lifeskim:mentionsumls-concept:C0221102lld:lifeskim
pubmed-article:16103092lifeskim:mentionsumls-concept:C1366587lld:lifeskim
pubmed-article:16103092lifeskim:mentionsumls-concept:C0333516lld:lifeskim
pubmed-article:16103092lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:16103092lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:16103092pubmed:issue16lld:pubmed
pubmed-article:16103092pubmed:dateCreated2005-8-16lld:pubmed
pubmed-article:16103092pubmed:abstractTextHepatocellular carcinomas (HCC) are drug-resistant tumors that frequently possess high telomerase activity. It was therefore the aim of our study to investigate the potential of telomerase-dependent virotherapy in multimodal treatment of HCC. In contrast to normal liver, HCC xenografts showed high telomerase activity, resulting in tumor-restricted expression of E1A by a telomerase-dependent replicating adenovirus (hTERT-Ad). Neither tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or chemotherapy alone nor the combined treatment with both agents resulted in significant destruction of HCC cells. Application of hTERT-Ad at low titers was also not capable to destroy HCC cells, but telomerase-dependent virotherapy overcame the resistance of HCC against TRAIL and chemotherapy. The synergistic effects are explained by a strong down-regulation of Mcl-1 expression through hTERT-Ad that sensitizes HCC for TRAIL- and chemotherapy-mediated apoptosis. To investigate whether down-regulation of Mcl-1 alone is sufficient to explain synergistic effects observed with virotherapy, Mcl-1 expression was inhibited by RNA interference. Treatment with Mcl-1-siRNA significantly enhanced caspase-3 activity after chemotherapy and TRAIL application, confirming that elimination of Mcl-1 is responsible for the drug sensitization by hTERT-Ad. Consistent with these results, heterologous overexpression of Mcl-1 significantly reduced the sensitization of hTERT-Ad transduced cells against apoptosis-inducing agents. Chemotherapy did not interfere with quantitative hTERT-Ad production in HCC cells. Whereas hTERT-Ad virotherapy alone was only capable to inhibit the growth of Hep3B xenografts, virochemotherapy resulted in vast destruction of the drug-resistant HCC. In conclusion our data indicate that telomerase-dependent virotherapy is an attractive strategy to overcome the natural resistance of HCC against anticancer drugs by elimination of Mcl-1.lld:pubmed
pubmed-article:16103092pubmed:languageenglld:pubmed
pubmed-article:16103092pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16103092pubmed:citationSubsetIMlld:pubmed
pubmed-article:16103092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16103092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16103092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16103092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16103092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16103092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16103092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16103092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16103092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16103092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16103092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16103092pubmed:statusMEDLINElld:pubmed
pubmed-article:16103092pubmed:monthAuglld:pubmed
pubmed-article:16103092pubmed:issn0008-5472lld:pubmed
pubmed-article:16103092pubmed:authorpubmed-author:WirthThomasTlld:pubmed
pubmed-article:16103092pubmed:authorpubmed-author:KubickaStefan...lld:pubmed
pubmed-article:16103092pubmed:authorpubmed-author:KühnelFlorian...lld:pubmed
pubmed-article:16103092pubmed:authorpubmed-author:ZenderLarsLlld:pubmed
pubmed-article:16103092pubmed:authorpubmed-author:RudolphKarl...lld:pubmed
pubmed-article:16103092pubmed:authorpubmed-author:MannsMichaelMlld:pubmed
pubmed-article:16103092pubmed:authorpubmed-author:DjojosubrotoM...lld:pubmed
pubmed-article:16103092pubmed:authorpubmed-author:WollerNormanNlld:pubmed
pubmed-article:16103092pubmed:authorpubmed-author:Fleischmann-M...lld:pubmed
pubmed-article:16103092pubmed:issnTypePrintlld:pubmed
pubmed-article:16103092pubmed:day15lld:pubmed
pubmed-article:16103092pubmed:volume65lld:pubmed
pubmed-article:16103092pubmed:ownerNLMlld:pubmed
pubmed-article:16103092pubmed:authorsCompleteYlld:pubmed
pubmed-article:16103092pubmed:pagination7393-402lld:pubmed
pubmed-article:16103092pubmed:dateRevised2008-7-9lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:meshHeadingpubmed-meshheading:16103092...lld:pubmed
pubmed-article:16103092pubmed:year2005lld:pubmed
pubmed-article:16103092pubmed:articleTitleTelomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1.lld:pubmed
pubmed-article:16103092pubmed:affiliationDepartment of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany.lld:pubmed
pubmed-article:16103092pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16103092pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16103092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16103092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16103092lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16103092lld:pubmed